A. Naleway

Meningococcal B Vaccination Patterns Across 10 Integrated Health Systems within Vaccine Safety Datalink, 2015-2023.

OBJECTIVE To examine patterns of vaccination with the meningococcal B vaccine (MenB) across 10 Vaccine Safety Datalink (VSD) healthcare systems. STUDY DESIGN We identified all MenB doses administered 2015-2023 to individuals ages 10-25 years at VSD sites. Each site was assigned to a US region: Western, Central, or Ea...

Effectiveness of RSV Prevention Strategies in US Infants: 2024-2025.

OBJECTIVE In 2023, 2 products, a long-acting monoclonal antibody (nirsevimab) and maternal respiratory syncytial virus (RSV) vaccination, were recommended in the United States to prevent severe RSV disease among infants in their first RSV season. Low uptake during the 2023 to 2024 RSV season limited effectiveness estim...

HPV antibody concentrations among male and female adolescents after single-dose 9-valent HPV vaccination.

Influenza Vaccine Effectiveness Against Influenza-Associated Hospitalizations and Emergency Department or Urgent Care Encounters Among Children and Adults-VISION, United States, 2024-2025 Season.

Background The 2024-2025 influenza season was the most severe in the United States (US) since 2017-2018, with co-circulation of both influenza A virus subtypes (H1N1 and H3N2). Influenza vaccine effectiveness (VE) has varied by season, setting, and patient characteristics. Methods Using electronic healthcare encounte...

Household Transmission of Human Metapneumovirus and Human Parainfluenza Viruses 1-4 in the United States, 2022-2024

Human metapneumovirus (HMPV) and human parainfluenza viruses (HPIV 1-4) are common causes of seasonal respiratory illness, but their household transmission dynamics remain poorly defined. We analyzed weekly symptom data and nasal swabs from a prospective household surveillance study in Washington and Oregon from June 2...

Immune correlates of risk for SARS-CoV-2 infection in children: a prospective, community-based cohort study

It is revealed that higher nucleocapsid-binding and Omicron-specific neutralizing antibodies significantly reduce infection risk, suggesting these markers could guide tailored vaccination strategies and risk assessments in pediatric populations.